- Completing $340m strategic acquisition of BioVision 

- Expanding facilities in Eugene, further growing kits and assays portfolio

- Supporting the growing demand of the sector and accelerating execution of 
strategic plan

Abcam (https://corporate.abcam.com/ ) (AIM:ABC; NASDAQ:ABCM), a global 
innovator in life sciences reagents and tools, today announces the successful 
completion of its acquisition of BioVision and the expansion of its immunoassay 
capacity in Eugene, OR.

Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg 

Across the life sciences sector, the events of the last 18 months have 
amplified the need for efficient workflows and robust data generation, to 
enable the faster delivery of positive outcomes for science and health. 
Widespread access to high-performance, reproducible, off-the-shelf assays and 
kits has become invaluable to enable the biopharma industry and academia to 
achieve meaningful advances at pace. To further support the growing demand of 
the sector and to strengthen its position in the assay market, Abcam today 
announces two significant developments, accelerating the execution of its 
strategic growth plan.

The addition of BioVision enhances Abcam's in-house innovation and adds scale 
to support the biochemical assay and cellular assay markets. The successful 
acquisition brings BioVision's product portfolio, capabilities, and 70-strong 
expert development and manufacturing teams into Abcam. The global research 
community will gain ready access to this portfolio of biochemical and 
cell-based assays via Abcam's global commercialization network.

Supplementing the acquisition, Abcam has doubled the footprint of its 
immunoassay kit R&D and manufacturing facility in Eugene, OR. This enhanced 
capacity is another component of Abcam's growth journey in the US and will 
further enable its commitment to support the research and biopharma sector 
globally. 

Alan Hirzel, CEO at Abcam, commented: "We are delighted to welcome our new 
colleagues to Abcam. Providing a platform for future growth and addition of new 
product lines, the acquisition of BioVision and expansion of our Eugene 
facility reinforce our commitment to the acceleration of scientific 
breakthroughs. Enabling scientists to reproducibly generate the robust results 
they need, faster, is essential   for the delivery of new innovations that can 
positively impact us all." 

Notes to Editors

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes 
high-quality biological reagents and tools that are crucial to research, drug 
discovery and diagnostics. Working across the industry, the Company supports 
life scientists to achieve their mission, faster. 

Abcam partners with life sciences organizations to co-create novel binders for 
use in drug discovery, in vitro diagnostics and therapeutics, driven by the 
Company's proprietary discovery platforms and world-leading antibody expertise. 

By constantly innovating its binders and assays, Abcam is helping advance the 
global understanding of biology and causes of disease, which enables new 
treatments and improved health. The Company's pioneering data-sharing approach 
gives scientists increased confidence in their results by providing validation, 
user comments and peer-reviewed citations for its 90,000 products. 

With 14 sites globally, many of Abcam's +1,600-strong team are located in the 
world's leading life sciences research hubs, complementing a global network of 
services and support. 

To find out more, please visit www.abcam.com and  www.abcamplc.com.


SOURCE: Abcam